en · de · es · fr · pt
tb-500-notes.peptides4800.com › Info › Thymosin Beta-4 Fragment Background — 2026 Update

Thymosin Beta-4 Fragment Background — 2026 Update

By Editorial Desk · published 2026-06-03 · last reviewed 2026-07-14 · Info

Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-07-14. Where a claim depends on a specific study, the study is described rather than over-claimed.

Thymosin Beta-4 Fragment Background

Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.

TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.

Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.

Handling, Stability and Analytical Detection

Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.

Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.

Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.

Tb-500 at a glance

PropertyValueNotes
Molecular classSynthetic peptideN-terminal fragment of thymosin beta-4
Residue countSevenSequence LKKTETQ
Approximate mass889 DaAcetylated seven-residue peptide
Common synonymsTB4 fragment, TB500Not identical to full-length TB4
Reported activityActin bindingObserved mainly in cell-free systems

Detection, Stability, and Regulatory Status

Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.

Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.

Related pages on this site

Thymosin Beta-4 Fragment Overview

The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.

TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.

Handling, Storage and Quality Checks

Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.

Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.

Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.

Handling, Storage, and Analytical Verification

Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.

Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.

The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.

Further detail

As soon as Heseltine was elected in March 1966, the seat of Tavistock was recommended for abolition by the Boundary Commission, divided between the new seats of West Devon (effectively a rural seat, where Heseltine would have had to compete for the candidacy with the sitting MP Peter Mills who had a strong local following) and Plymouth Sutton (which had a strong Powellite/Monday Club element—they eventually selected the right-winger Alan Clark). Several of his activists attempted to persuade him to apply for Plymouth Sutton, but he was not interested, wanting a seat nearer London. In the event, the implementation of the Boundary Review was postponed for partisan reasons until after the next general election by Home Secretary James Callaghan (on the pretext of waiting until after the Redcliffe-Maud Report on local government reorganisation). Heseltine therefore defended Tavistock at the 1970 general election, achieving a better than average swing to the Conservatives.

=== Uptake === Tau protein has been found in the extracellular environment including Cerebrospinal fluid (CSF) and Interstitial fluid (ISF) under physiological and pathological conditions. Low-density lipoprotein receptor-related protein 1 (LRP1) has been shown as the receptor for Tau internalization into cells. However, studying Tau uptake in human neurons revealed that physiological Tau monomers mainly use LRP1 for internalization, while the uptake of pathological Tau aggregates depend on heparan sulfate proteoglycans.

==== Laboratory use ==== In the laboratory, THF is a popular solvent when its water miscibility is not an issue. It is more basic than diethyl ether and forms stronger complexes with Li+, Mg2+, and boranes. It is a popular solvent for hydroboration reactions and for organometallic compounds such as organolithium and Grignard reagents. Thus, while diethyl ether remains the solvent of choice for some reactions (e.g., Grignard reactions), THF fills that role in many others, where strong coordination is desirable and the precise properties of ethereal solvents such as these (alone and in mixtures and at various temperatures) allows fine-tuning modern chemical reactions. Commercial THF contains substantial water that must be removed for sensitive operations, e.g. those involving organometallic compounds. Although THF is traditionally dried by distillation from an aggressive desiccant such as elemental sodium, molecular sieves have been shown to be superior water scavengers.

=== Notable applications === With the development of native chemical ligation in 1994, total chemical synthesis of pairs of D-protein and L-protein enantiomers became feasible. In the first practical application to solving an unknown structure, racemic and quasi-racemic X-ray crystallography were used to determine the structure of snow flea anti-freeze protein. In the course of that work it was observed that racemic and even quasi-racemic protein mixtures dramatically facilitated the formation of diffraction quality, centrosymmetric crystals. Quasi-racemates are formed by mirror image protein molecules that are not true enantiomers but which are sufficiently similar mirror image objects to form ordered pseudo-centrosymmetric arrays. Subsequently, pairs of racemic and quasi-racemic protein molecules prepared by total chemical synthesis have been shown to dramatically increase the rate of success in forming diffraction-quality crystals from a wide range of globular protein molecules. Rv1738, a protein of Mycobacterium tuberculosis is the most up-regulated gene product when M. tb enters persistent dormancy. Preparations of recombinantly expressed Rv1738 L-protein resisted extensive attempts to form crystals. A racemic mixture of the chemically synthesized D-protein and L-protein forms of Rv1738 gave crystals in the centrosymmetric space group C2/c. The structure, containing L-protein and D-protein dimers in a centrosymmetric space group, revealed structural similarity to 'hibernation-promoting factors' that can bind to ribosomes and suppress translation.

Sources: en.wikipedia.org

Background from the literature

== Overdose == Doses of methenamine much higher than usual have been clinically studied and found to produce significant toxicity. More specifically, doses of 8 g per day (4–8-fold usual doses) for 3 to 4 weeks resulted in bladder irritation, painful and frequent urination, albuminuria (albumin in urine), crystalluria (crystals in urine), and hematuria (blood in urine). Some of these side effects are thought to be due to high levels of formaldehyde in the bladder and consequent irritation. Doses of methenamine of up to 10 to 20 g/day have also been studied and found to be tolerable without major toxicity. When methenamine was first introduced in the late 1800s and early 1900s, doses of 15 to 30 g per day were commonly employed and doses of up to 60 to 180 g per day were tried in some cases. Toxic effects of such high doses included urinary tract and bladder irritation, frequent urination, strangury, and hematuria. Animal studies employing double the modern human dosage of methenamine for 6 to 12 months found no adverse effects.

Breastfeeding support is universal among major health and children's organizations. WHO states, "Breast milk is the ideal food for the healthy growth and development of infants; breastfeeding is also an integral part of the reproductive process with important implications for the health of mothers." Breastfeeding is associated with a lowered risk of several diseases in both mothers and babies. Comparing infants that were exclusively breastfed for at least 3 months with never-breastfed infants, the American Academy of Pediatrics reported that in the first year of life breastfed babies averaged about $400 in savings of health care costs.

The matrix can be used to tune the instrument to ionize the sample in different ways. As mentioned above, acid-base like reactions are often utilized to ionize the sample, however, molecules with conjugated pi systems, such as naphthalene like compounds, can also serve as an electron acceptor and thus a matrix for MALDI/TOF. This is particularly useful in studying molecules that also possess conjugated pi systems. The most widely used application for these matrices is studying porphyrin-like compounds such as chlorophyll. These matrices have been shown to have better ionization patterns that do not result in odd fragmentation patterns or complete loss of side chains. It has also been suggested that conjugated porphyrin like molecules can serve as a matrix and cleave themselves eliminating the need for a separate matrix compound.

=== Research for therapeutic use === The classification of L-serine as a non-essential amino acid has come to be considered as conditional, since vertebrates such as humans cannot always synthesize optimal quantities over entire lifespans. Safety of L-serine has been demonstrated in an FDA-approved human phase I clinical trial with Amyotrophic Lateral Sclerosis, ALS, patients (ClinicalTrials.gov identifier: NCT01835782), but treatment of ALS symptoms has yet to be shown. A 2011 meta-analysis found adjunctive sarcosine to have a medium effect size for negative and total symptoms of schizophrenia. There also is evidence that L‐serine could acquire a therapeutic role in diabetes. D-Serine is being studied in rodents as a potential treatment for schizophrenia. D-Serine also has been described as a potential biomarker for early Alzheimer's disease (AD) diagnosis, due to a relatively high concentration of it in the cerebrospinal fluid of probable AD patients. D-serine, which is made in the brain, has been shown to work as an antagonist/inverse co-agonist of t-NMDA receptors mitigating neuron loss in an animal model of temporal lobe epilepsy. D-Serine has been theorized as a potential treatment for sensorineural hearing disorders such as hearing loss and tinnitus.

Titration: Metrohm offers different titration systems, including potentiometric, thermometric, and Karl Fischer titrators. The Omnis software provides a modular and scalable framework for titration workflows, including options for integrated sample handling and digital data management. Ion chromatography (IC): Metrohm provides instruments for determining anions, cations, and organic substances at trace and ultra-trace levels, used in industries such as pharmaceuticals, chemicals, and environmental analysis. Electrochemistry and Voltammetry: Metrohm supplies potentiostats, galvanostats, and accessories for electrochemical research and trace analysis of metals. Spectroscopy: The company's spectroscopy range includes instruments for near-infrared (NIR) and Raman spectroscopy, such as portable and laboratory Raman analyzers and NIR spectrometers. Process analytics: Metrohm offers modular systems for real-time online monitoring of industrial processes using titration, ion chromatography, and spectroscopy. Metrohm collaborates with external partners to develop fully automated laboratory robots for sample preparation and analysis. Metrohm also offers pH meters, conductivity meters, dosing systems, and software for data management and compliance.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.

What activity is attributed to this sequence?

The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.

Is there a standard purity specification?

Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.

How should lyophilised peptide powder be stored?

Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.

Network